[{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Apollomics Inc","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Apollomics Inc"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescent Biopharma \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apollomics Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ GlycoMimetics"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ GlycoMimetics"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Zhejiang CrownMab Biotech Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Zhejiang CrownMab Biotech Co. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Zhejiang CrownMab Biotech Co. Ltd"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"GlycoMimetics | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ GlycoMimetics | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ GlycoMimetics | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Zhejiang CrownMab Biotech Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Zhejiang CrownMab Biotech Co. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Zhejiang CrownMab Biotech Co. Ltd"},{"orgOrder":0,"company":"Malika Kapadia","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase I","graph3":"Malika Kapadia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Malika Kapadia \/ GlycoMimetics","highestDevelopmentStatusID":"6","companyTruncated":"Malika Kapadia \/ GlycoMimetics"},{"orgOrder":0,"company":"Lena Napolitano, MD","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Lena Napolitano, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lena Napolitano, MD \/ GlycoMimetics","highestDevelopmentStatusID":"7","companyTruncated":"Lena Napolitano, MD \/ GlycoMimetics"}]
Find Clinical Drug Pipeline Developments & Deals for Uproleselan
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
